Millennium Management
BBLG

Millennium Management’s Bone Biologics BBLG Stock Holding History

Millennium Management’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12
Closed -$5K – 6111
2023
Q1 		$5K Sell
12
-21
-64% -$8.77K ﹤0.01% 6130
2022
Q4 		$10K Buy
+33
New +$18.6K ﹤0.01% 6183

Other funds holding BBLG

Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Millennium Management's BBLG Position: Q2 2023 in Review

Millennium Management sold out of Bone Biologics (BBLG) in Q2 2023, closing a stake of 12 shares — an estimated $5K sold.

Millennium Management first reported a position in BBLG in Q4 2022 and held it in 2 quarters. The position peaked at $10K in Q4 2022. 6 funds tracked by Wall St. Rank hold BBLG as of Q2 2023.

  • Millennium Management reported no remaining Bone Biologics position as of Q2 2023 after selling out during the quarter.
  • Millennium Management sold 12 Bone Biologics shares in Q2 2023, an estimated $5K.
  • Millennium Management first reported a position in Bone Biologics in Q4 2022 and held it in 2 quarters.
  • Millennium Management's Bone Biologics position peaked at $10K in Q4 2022.
  • 6 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2023.

Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.